Cellectar Biosciences CLRB 深 滬
等待開盤 11-04 09:30:00 美东时间
1.31
+0.090
+7.38%
華盛通- 最 高1.31
- 今 開1.24
- 成交量 14.09万股
- 最 低 1.2274
- 昨 收 1.22
- 總市值 1238.23万
- 52周最高 4.70
- 市盈率 靜 --
- 換手率 1.49%
- 52周最低 1.12
- 委 比 -92.94%
- 總股本 945.21万
- 歷史最高 276000.00
- 量 比 1.55
- 振 幅 6.77%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cellectar Biosciences Inc.收跌1.23%，成交额6.6万美元
10月31日，Cellectar Biosciences Inc.（CLRB）收跌1.23%，报1.21美元，成交额6.6万美元，市值1138.98万美元。 行...
10-31 07:54
Cellectar Biosciences Inc.收跌1.61%，成交额13.69万美元
10月30日，Cellectar Biosciences Inc.（CLRB）收跌1.61%，报1.22美元，成交额13.69万美元，市值1153.16万美元...
10-30 07:56
Cellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a Range of B-cell Malignancies FLORHAM PARK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) --...
10-27 19:16
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Cellectar Biosciences reported a case study demonstrating a durable complete response in a patient with aggressive, relapsed DLBCL treated with a single dose of iopofosine I 131. The patient achieved complete remission within 85 days and remained disease-free for over eight years without further anticancer therapy. This highlights the potential of iopofosine I 131, a phospholipid drug conjugate delivering iodine-131 to cancer cells, across B-cell...
10-27 11:15
Cellectar Biosciences Inc.收涨4.07%，成交额17.21万美元
10月22日，Cellectar Biosciences Inc.（CLRB）收涨4.07%，报1.28美元，成交额17.21万美元，市值1209.87万美元...
10-22 08:02
Cellectar Biosciences Inc.收跌4.2%，成交额41.31万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 08:03
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Cellectar Biosciences announced positive efficacy results from a subgroup analysis of 24 patients with relapsed or refractory Waldenström macroglobulinemia (WM) treated with iopofosine I 131 immediately after Bruton Tyrosine Kinase inhibitor (BTKi) therapy in their Phase 2b CLOVER WaM trial. The analysis showed an 87.5% overall response rate (ORR), 79.2% major response rate (MRR), 100% clinical benefit rate (CBR), and a median duration of respons...
10-15 11:00
Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And Warrants
Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And Warrants
08-15 00:17
Cellectar Biosciences 13G Filing Shows StemPoint Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 845,740 Shares Including Pre-Funded Warrants
Cellectar Biosciences 13G Filing Shows StemPoint Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 845,740 Shares Including Pre-Funded Warrants
08-15 00:17
Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) Estimate
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.48) by 18.75 percent. This is a 83.19 percent increase over losses of $(3.39) per share from the same period last year.
08-13 19:03
